Recursion Pharmaceuticals (NASDAQ:RXRX) Director Blake Borgeson Sells 30,000 Shares of Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $3.52, for a total transaction of $105,600.00. Following the sale, the director owned 6,199,863 shares in the company, valued at approximately $21,823,517.76. This trade represents a 0.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, April 7th, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.10, for a total transaction of $93,000.00.

Recursion Pharmaceuticals Stock Down 4.7%

Shares of RXRX opened at $3.27 on Friday. The company has a quick ratio of 5.50, a current ratio of 5.50 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average price of $3.40 and a two-hundred day moving average price of $4.12. The stock has a market cap of $1.72 billion, a price-to-earnings ratio of -2.72 and a beta of 1.05. Recursion Pharmaceuticals, Inc. has a 12 month low of $2.80 and a 12 month high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.08. The company had revenue of $6.47 million for the quarter, compared to analyst estimates of $15.78 million. Recursion Pharmaceuticals had a negative return on equity of 54.22% and a negative net margin of 842.95%.The company’s revenue was down 56.8% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.50) EPS. Equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.08 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. International Assets Investment Management LLC acquired a new position in Recursion Pharmaceuticals during the 4th quarter worth about $31,000. Integral Investment Advisors Inc. acquired a new stake in Recursion Pharmaceuticals in the 1st quarter valued at about $39,000. Sequoia Financial Advisors LLC bought a new position in shares of Recursion Pharmaceuticals in the fourth quarter worth about $41,000. MQS Management LLC bought a new position in shares of Recursion Pharmaceuticals in the first quarter worth about $41,000. Finally, Allworth Financial LP lifted its position in shares of Recursion Pharmaceuticals by 85.6% during the third quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock worth $47,000 after purchasing an additional 4,403 shares in the last quarter. 89.06% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on RXRX. Needham & Company LLC reiterated a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday. Wall Street Zen lowered shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st. JPMorgan Chase & Co. reduced their price target on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Finally, Bank of America decreased their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $9.20.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.